ERBC conducts acute, subacute and chronic toxicity studies (up to one year) in rodent and non-rodent species, including pharmacokinetic, toxicokinetic, recovery period.
- Single dose and dose range finding
- Repeated dose toxicity (up to 52 weeks)
- Administration routes: oral, intravenous (up to 4 weeks), subcutaneous, intramuscular (up to 4 weeks) and intraperitoneal (at an appropriate dose regimen)
- Single dose and dose range finding
- Repeated dose toxicity (up to 52 weeks)
- Administration routes: oral gavage, diet, dermal, intravenous by bolus or continuous infusion (up to 13 weeks), subcutaneous, intramuscular (up to 4 weeks), intranasal, intratracheal, intraperitoneal (at an appropriate dose regimen), intradermal and intravesical
- Single dose and dose range finding
- Repeated dose toxicity (up to13 weeks)
- Administration routes: oral gavage, dermal, subcutaneous, intramuscular (up to 4 weeks), intra-articular, ocular and intravitreal (at an appropriate dose regimen)
- Dose range finding study
- Repeated dose toxicity (up to 52 weeks)
- Administration routes: oral gavage, capsules, diet, intravenous by bolus or continuous infusion (up to 13 weeks), subcutaneous, dermal, ocular, intramuscular, intranasal and intraperitoneal (at an appropriate dose regimen)
- Dose range finding study
- Repeated dose toxicity (up to 39 weeks)
- Administration routes: oral gavage, capsules, intravenous, subcutaneous, dermal, ocular, intramuscular, intradermal and intra-articular (at an appropriate dose regimen)
- Dose range finding study
- Repeated dose toxicity (up to 39 weeks)
- Administration routes: oral gavage, intravenous by bolus or continuous infusion (up to 8 weeks), subcutaneous, ocular and intramuscular
- Dose range finding study
- Repeated dose toxicity (up to 52 weeks)
- Administration routes: oral gavage, intravenous by bolus or continuous infusion (up to 4 weeks), subcutaneous, ocular and intramuscular
Mouse
Rat
Dog
Rabbit
Marmoset
Ferret
Cynomolgus Monkeys
Guinea Pig
